A randomized controlled trial of green tea catechins in protection against ultraviolet radiation–induced cutaneous inflammation

Mark D Farrah, Anna Nicolaou, Kayleigh A Clarke, Sarah Mason, Karen A Massey, Tristan P Dew, Rachel EB Watson, Gary Williamson, and Lesley E Rhodes

Centre for Dermatology, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; Manchester Pharmacy School, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom; School of Food Science and Nutrition, University of Leeds, Leeds, United Kingdom; and Bradford School of Pharmacy, Faculty of Life Sciences, University of Bradford, Bradford, United Kingdom

ABSTRACT
Background: Safe systemic protection from the health hazards of ultraviolet radiation (UVR) in sunlight is desirable. Green tea is consumed globally and is reported to have anti-inflammatory properties, which may be mediated through the impact on cyclooxygenase and lipoxygenase pathways. Recent data suggest that green tea catechins (GTCs) reduce acute UVR effects, but human trials examining their photoprotective potential are scarce.

Objective: We performed a double-blind, randomized, placebo-controlled trial to examine whether GTCs protect against clinical, histologic, and biochemical indicators of UVR-induced inflammation.

Design: Healthy adults (aged 18–65 y, phototypes I–II) were randomly allocated to 1350 mg encapsulated green tea extract (540 mg GTC) with 50 mg vitamin C or placebo twice daily for 3 mo. Impact on skin erythema, dermal leukocytic infiltration, and concentrations of proinflammatory eicosanoids was assessed after solar-simulated UVR challenge, and subject compliance was determined through assay of urinary GTC metabolite epigallocatechin glucuronide.

Results: Volunteers were assigned to the active (n = 25) or the placebo (n = 25) group. After supplementation, median (IQR) sunburn threshold (minimal erythema dose) was 28 (20–28) and 20 (20–28) mJ/cm² in the active and placebo groups, respectively (nonsignificant), with no difference in AUC analysis for measured erythema index after a geometric series of 10 UVR doses. Skin immunohistochemistry showed increased neutrophil and CD3+ T-lymphocyte numbers post-UVR in both groups (P < 0.01) with no statistically significant differences between groups after supplementation. Cyclooxygenase and lipoxygenase metabolites prostaglandin E₂ (vasodilator) and 12-hydroxyeicosatetraenoic acid (chemoattractant), respectively, increased after UVR (P < 0.05), with no differences between supplementation groups.

Conclusion: Oral GTC (1080 mg/d) with vitamin C over 3 mo did not significantly reduce skin erythema, leukocyte infiltration, or eicosanoid response to UVR inflammatory challenge. This trial was registered at clinicaltrials.gov as NCT01032031. Am J Clin Nutr 2015;102:608–15.

Keywords: green tea catechins, human skin, inflammation, photoprotection, ultraviolet radiation

INTRODUCTION
The skin has important roles in the body’s defense against harmful stimuli. Ultraviolet radiation (UVR) in sunlight is a key environmental trigger of acute adverse events, including dose-related inflammation (sunburn), photosensitivity, immunosuppression, and DNA damage, with repeated exposure leading to chronic photodamage and photocarcinogenesis. Topical sunscreens can protect by absorbing and scattering UVR but have drawbacks, including generally infrequent application outside of holiday times and inadequate application methods, with uneven spread and use at surface density considerably lower than the manufacturers’ sunscreen testing conditions.

The acute response of the skin to UVR is orchestrated by cells within the epidermal and dermal layers that release mediators producing acute inflammation, which presents clinically as erythema and histologically as a dermal leukocytic infiltrate. UVR-induced oxidative stress stimulates expression and activity of cytosolic phospholipase A₂, leading to increased production of free arachidonic acid, which can be metabolized by cyclooxygenases and lipoxygenases to a wide range of eicosanoids, many of which play roles in inflammation, notably the cyclooxygenase-2 product prostaglandin (PG) E₂, a major mediator of cutaneous inflammatory processes.

1Supported by grants BB/G005575/1 (to LER), BB/G005540/1 (to AN), and BB/G005599/1 (to GW) from the Biotechnology and Biological Sciences Research Council, Diet and Health Research Industry Club. This is an open access article distributed under the CC-BY license (http://creativecommons.org/licenses/by/3.0/).

2Supplemental Table 1 is available from the “Supplemental data” link in the online posting of the article and from the same link in the online table of contents at http://ajcn.nutrition.org.

*To whom correspondence should be addressed. E-mail: lesley.e.rhodes@manchester.ac.uk.

1Abbreviations used: EGCG, (-)-epigallocatechin-3-O-gallate; GTC, green tea catechin; HETE, hydroxyeicosatetraenoic acid; hpf, high-power field; MED, minimal erythema dose; PG, prostaglandin; UVR, ultraviolet radiation.

Received January 28, 2015. Accepted for publication June 17, 2015. First published online July 15, 2015; doi: 10.3945/ajcn.115.107995.
of UVR-induced erythema (8, 9), and the 12-lipoxygenase–derived 12-hydroxyeicosatetraenoic acid (HETE), a potent leukocyte chemotactrant (9–11) in the sunburn response.

There is considerable interest in the potential benefits to health of green tea, which is widely consumed in many parts of the world. In addition to a broad literature relating to their chemopreventive activities (12, 13), green tea catechins (GTCs) have anti-inflammatory properties (14, 15) and are part of the polyphenol group, which can reduce the expression and activity of cyclooxygenase-2 and several lipoxygenase isoforms (16–19). The green tea polyphenol (→)-epigallocatechin-3-gallate (EGCG) has been reported to reduce cyclooxygenase-2 expression, in addition to UVB-mediated activation of nuclear transcription factor κB and neutrophil migration in vitro (20–23), and oral GTCs were protective against UVR-induced skin inflammation as well as carcinogenesis in hairless mice (24). In humans, topical application of GTCs before UVR reduced cutaneous erythema, leukocyte infiltration, and DNA damage induced by UVR (25), whereas oral consumption was reported to increase the clinical erythema threshold to UVR (26). In a before-after pilot study, 12-wk oral GTCs led to incorporation of GTC metabolites into skin and modest protection against UVR-induced erythema, alongside reduced 12-HETE production (27).

The above findings indicated the requirement for a double-blind, randomized controlled trial of adequate sample size to examine in more depth the photoprotective potential of oral GTCs against acute UVR insult. We have conducted such a study of 3-mo oral GTCs with low-dose vitamin C in healthy humans, evaluating its ability to protect against UVR-induced inflammation by 1) visual and objective assessment of clinical erythema after a range of UVR doses, 2) histologic assessment of skin leukocytic infiltrate, and 3) quantification of the major proinflammatory cyclooxygenase- and lipoxygenase-derived mediators upregulated in sunburn, PGE$_2$, and 12-HETE.

METHODS

Study design

Fifty healthy white adults (aged 18–65 y), male and female, Fitzpatrick sun-reactive skin types I–II, were recruited by open advertisement. Exclusion criteria were history of skin cancer or photosensitivity disorder, sunbed use/sunbathing in the 3 mo before the study, taking photoactive medication or nutritional supplements, consuming >2 cups of tea/d, or currently pregnant or breastfeeding. Ethical approval was obtained from the North Manchester Research Ethics Committee (reference 08/H1006/79). Written informed consent was obtained from the participants and the study adhered to Declaration of Helsinki principles. The study was conducted in the Photobiology Unit, Dermatology Centre, Salford Royal Hospital, Manchester, United Kingdom, between November 2010 and August 2011. Subjects were randomly assigned to receive green tea extract plus vitamin C or placebo maltodextrin (1:1; block randomization with random block size between 4 and 8; StatsDirect v2.7.8, StatsDirect Ltd.). Containers containing active and placebo supplement were sequentially numbered. Subjects and investigators were blinded to the intervention, and the randomization code was held securely until completion of the study.

Green tea supplements were gelatin capsules each containing 450 mg green tea extract (180 mg GTC) (27) and a further set of capsules each containing 25 mg vitamin C. Actively supplemented subjects took 3 green tea and 2 vitamin C capsules twice daily (with breakfast and evening meal; total daily dose 1080 mg GTC, 100 mg vitamin C; Table 1) for 12 wk. Low-dose vitamin C stabilizes the green tea extract in the gut lumen and has been shown to have no impact itself on UVR erythema (28, 29). Placebo subjects took supplements comprising maltodextrin in gelatin capsules of identical appearance to those containing green tea and vitamin C. The primary outcome was change in the minimal erythema dose (MED) of UVR at 12 wk. Secondary outcomes were change in UVR-induced neutrophils and CD3$^+$ T lymphocytes in skin biopsy sections, as well as PGE$_2$ and 12-HETE in suction blister fluid at 12 wk. All supplements were provided by Nestec Ltd. and packaged in bottles with identical appearance by Laboratoire LPH. Compliance was assessed by counting residual capsules in dispensed containers returned by volunteers and measurement of the green tea urinary marker epigallocatechin glucuronide as described below.

UVR exposure and assessment of erythema response

Exposures were performed by using a solar simulator with emission of UVB and UVA mimicking that of sunlight (emission 290–400 nm; 5% UVB, 95% UVA; Newport Spectra-Physics Ltd). Irradiance was measured 10 cm from the source before each irradiation by using a radiometer (model IL 730A; International Light) calibrated for use with the light source to ensure consistency of doses applied.

The MED of UVR (i.e., the sunburn threshold) for each subject was assessed at baseline and postsupplementation, after application of a geometric series of 10 doses of solar-simulated UVR (erythemally weighted, 7–80 mJ/cm$^2$) to upper buttock skin (1-cm-diameter circular sites). Irradiated sites were examined visually after 24 h, with the MED defined as the lowest dose producing visually discernible erythema. Erythema intensity at each of the 10 UVR-exposed sites was quantified by using a reflectance instrument (Diastron). Readings were taken in triplicate from each exposed site and from adjacent unexposed skin and erythema expressed as the difference between these readings (ΔE). Dose-response modeling was performed by using a dedicated data analysis package (Regional Medical Physics Department, Gateshead & Tyneside Health Authority) to calculate each subject’s $D_{90}$, the UVR dose producing a ΔE of 30 arbitrary units, which is a threshold value approximating an individual’s visual MED.

| TABLE 1 |
| ----------------- | ------------ |
| Green tea constituent | Amount, mg |
| Gallic acid | 1.8 |
| Catechin | 12.6 |
| Epicatechin | 75.0 |
| Gallocatechin | 74.4 |
| Epigallocatechin | 295.8 |
| Catechin gallate | 1.8 |
| Epicatechin gallate | 156.0 |
| Gallocatechin gallate | 28.0 |
| Epigallocatechin gallate | 435.6 |
Skin biopsy and suction blister fluid sampling

At 24 h before skin tissue and blister fluid sampling, doses of UVR of 3× the individual’s presupplementation MED were given to sites on one buttock to provoke an inflammatory response sufficient to significantly elevate cutaneous eicosanoid concentrations (9). UVR-exposed and UVR-protected areas of upper buttock skin were sampled at baseline and post-supplementation; UVR exposures were limited to one buttock, and the other buttock provided the unexposed skin and blister fluid samples. Skin punch biopsy specimens (5 mm diameter) were taken after intradermal injection of lignocaine as described (9), snap frozen, and stored at −80°C. Suction blisters were raised by using suction cups with a central aperture diameter of 1 cm and vacuum of 250 mm Hg as described previously (9). Skin blister fluid was aspirated with a 23-gauge needle, snap frozen in liquid nitrogen, and stored at −80°C until analysis.

Immunohistochemical staining and assessment

Monoclonal anti–neutrophil elastase (clone NP57) and polyclonal anti-CD3 antibodies were obtained from Dako UK Ltd. Briefly, frozen biopsy specimens were sectioned (5 μm) and endogenous peroxidase activity blocked by incubation in 0.6% (vol:vol) hydrogen peroxide in methanol. Sections were incubated overnight at 4°C with primary antibody and then visualized by using the ImmPRESS system or Vectastain Elite ABC kit (Vector Laboratories Ltd.) for neutrophil elastase and CD3, respectively. All sections were blinded and randomized before assessment. For each biopsy sample, 3 high-power fields (hpf) were assessed microscopically from each of 3 biopsy sections. Cell number per hpf was determined for neutrophils and CD3+ T lymphocytes.

Analysis of skin blister fluid

Eicosanoids in skin blister fluid were quantified by liquid chromatography coupled to electrospray ionization tandem mass spectrometry as described previously (30–32). Briefly, skin fluid samples (typically 50–200 μL) were diluted with methanol-water (15% w/w) up to 3 mL. Internal standards (40 ng PGF2-α and 80 ng 12-HETE) were then added and resultant solutions acidified to pH 3.0, followed by solid-phase extraction (C18-E cartridges; Phenomenex) to reduce matrix effects and semi-purify the lipid mediators. Eicosanoids were analyzed on a C18 column (Luna 5 μm; Phenomenex) to reduce matrix effects and semi-purify the lipid mediators. Eicosanoids were analyzed on a C18 column (Luna 5 μm; Phenomenex) by using a Waters Alliance 2695 HPLC pump coupled to a triple-quadrupole mass spectrometer equipped with an electrospray ionization probe (Quattro Ultima; Waters). Instrument control and data acquisition were performed by using MassLynx 4.0 software (Waters). Multiple-reaction monitoring transitions used were as follows: PGE2, m/z 351 > 271; PGE1, m/z 353 > 317; PGF2, m/z 349 > 269; PGJ2, m/z 333 > 271; PGI2, m/z 353 > 317; PGD2, m/z 351 > 271; PGF2α, m/z 353 > 193; 13,14-dihydro-15-keto-PGE2, m/z 351 > 333; 13,14-dihydro-15-keto-PGE1, m/z 353 > 335; 12-HETE, m/z 319 > 179; 11-HETE, m/z 319 > 167; 15-HETE, m/z 319 > 175; 15-hydroxyeicosatetraenoic acid, m/z 321 > 221; 9-hydroxyoctadecadienoic acid, m/z 295 > 171; and 13-hydroxyoctadecadienoic acid, m/z 295 > 195.

Urinary analysis of GTC metabolites

The urinary GTC metabolite epigallocatechin glucuronide was assayed by liquid chromatography–tandem mass spectrometry as previously described (33) to establish compliance with supplementation. Volunteers provided 24-h urine samples before supplementation and after 1 d, 6 wk, and 12 wk of supplementation.

Statistical analyses

Based on previous oral flavonoid photoprotection studies (34, 35), a sample size of at least 22 subjects per group was estimated to be required to detect a 25% difference in the MED and UVR erythema dose-response between groups, at a 5% significance level with 90% power. Differences in UVR-induced inflammatory and eicosanoid responses between active and placebo groups post-supplementation were compared by ANCOVA of ln-transformed data with baseline data as the covariate. Intent to treat was the primary analysis for comparisons of outcomes between treatment groups with multiple imputation of missing data (n = 50). A per-protocol analysis was also performed (n = 45) to assess effectiveness of the supplementation. Wilcoxon’s Signed Rank test was used to compare unexposed and UVR-exposed skin within groups. Analyses were performed by using SPSS 20 (SPSS, Inc.). Erythema dose-response curves were analyzed by using GraphPad Prism (v5.01; GraphPad Software). Statistical significance was accepted at P < 0.05.

RESULTS

Study subjects and compliance

Of the 50 subjects recruited to the study, 25 were randomly allocated to active supplementation and 25 to placebo. Baseline characteristics of subjects are shown in Table 2. Four subjects in the active group were noncompliant; 2 had a low concentration of epigallocatechin glucuronide in urine at week 12, and 2 had missing urine samples for day 1 and week 12. One subject in the placebo group was noncompliant due to a high concentration of green tea metabolites in urine at day 1 (Figure 1). The BMI (in kg/m²) of the participants was unchanged throughout the study, with a mean ± SD of 27.7 ± 5.0 and 25.5 ± 4.0 in the active group and 27.9 ± 5.4 and 25.3 ± 3.8 in the placebo group at the 6- and 12-wk points, respectively. The supplement was well tolerated; 6 subjects (5 in the active group and 1 in the placebo group) reported occasional mild nausea after ingestion.

### Table 2
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Active (n = 25)</th>
<th>Placebo (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>36 ± 13.6</td>
<td>35 ± 12.3</td>
</tr>
<tr>
<td>Sex, M/F, n</td>
<td>6/19</td>
<td>7/18</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.9 ± 5.4</td>
<td>25.5 ± 3.8</td>
</tr>
<tr>
<td>Skin type, I/II, n</td>
<td>3/22</td>
<td>1/24</td>
</tr>
<tr>
<td>MED, µg/cm²</td>
<td>28 (12–48)</td>
<td>28 (7–48)</td>
</tr>
</tbody>
</table>

*Mean ± SD (all such values).*  
*MED, minimal erythema dose.*  
*Median; range in parentheses (all such values).*
Urinary excretion of epigallocatechin glucuronide

Urinary excretion of the green tea metabolite epigallocatechin glucuronide by compliant participants in the active group is shown in Figure 2. At baseline, 1 subject in the active group had a low concentration of urinary epigallocatechin glucuronide (AUC = 2094), whereas for all other subjects, the metabolite was not detected. At 6 wk, mean concentration (AUC) in the active group was 75,381 rising to 89,626 at 12 wk. In the placebo group, epigallocatechin glucuronide was undetectable in all subjects pre- and postsupplementation.

UVR erythema responses

Postsupplementation, there was no statistically significant difference in visual threshold erythema, that is, in the median MED between the active (28 mJ/cm²; range: 16–48) and placebo (20 mJ/cm²; range: 7–48) groups (P = 0.47; Figure 3A). AUC analysis for the measured erythema induced by a series of 10 UVR doses also revealed no statistically significant difference in the UVR erythema dose-response between the 2 groups at baseline (mean 3423 vs. 3573, respectively; P = 0.67; Figure 3B) or post-supplementation (mean 3555 vs. 3839; P = 0.44; Figure 3C). Within-group analyses showed there was no statistically significant difference in median MED post-supplementation compared with baseline for the active group (both 28 mJ/cm²; P = 0.17) or placebo group (20 and 28 mJ/cm², respectively; P = 0.12).

Dermal leukocytic infiltration

Immunohistochemical assessment of skin sections demonstrated that the number of neutrophils and CD3⁺ T lymphocytes in skin irradiated with 3× MED UVR was statistically significantly higher than in unirradiated skin in both groups, both at baseline and post-supplementation (all P < 0.01; Figure 4). There was no statistically significant difference in neutrophil numbers in UVR-irradiated skin between groups post-supplementation (P = 0.85). Neutrophil numbers in UVR-exposed skin were mean ± SEM of 46.2 ± 5.0 cells/hpf at baseline and 38.4 ± 4.1 cells/hpf post-supplementation (P = 0.06) in the active group and
44.2 ± 4.3 and 40.8 ± 5.2 cells/hpf, respectively (P = 0.37), in the placebo group. There was little change in the number of CD3⁺ T cells in UVR-exposed skin from subjects in the active group postsupplementation compared with baseline, with no statistically significant difference between active and placebo (P = 0.62; Figure 4). Similarly, no statistically significant difference between treatment groups was found after multiple imputation or per-protocol analyses.

**Cutaneous production of eicosanoids**

We examined 15 eicosanoids, including those of principal interest (i.e., PGE₂ and 12-HETE). Concentrations of both PGE₂ and 12-HETE in suction blister fluid from skin irradiated with 3× MED UVR were significantly higher (mean increase post-UVR of 161% for PGE₂ and 233% for 12-HETE) than in unirradiated skin in both groups, at baseline and post-supplementation (all P < 0.05; Figure 5). Postsupplementation, the mean ± SEM concentration of PGE₂ in blister fluid from UVR-exposed skin of subjects in the active group (110.3 ± 17.3 pg/μL) was not significantly different from placebo (137.3 ±
GREEN TEA CATECHINS AND UVR-INDUCED INFLAMMATION

16.3 pg/µL; \( P = 0.35 \); Figure 5A). Similarly, there was no significant difference in concentration of 12-HETE in UVR-exposed skin between the active group (43.1 ± 4.6 pg/µL) and the placebo group (38.9 ± 4.9 pg/µL; \( P = 0.45 \); Figure 5B). Results were comparable after multiple imputation and per-protocol analyses. Results for all eicosanoid species currently assayed in blister fluid are presented in **Supplemental Table 1**. There was no statistically significant impact of GTC supplementation on basal or UVR-induced production of these eicosanoids.

**DISCUSSION**

Green tea is suspected to have benefits to health spanning a wide range of inflammatory and immune-mediated disorders (36), in addition to chemopreventive properties. However, limited information is available from human studies, with most data arising from experimental study of the most abundant GTC: EGCG. Skin is exposed to and requires protection from environmental UVR and itself provides an accessible organ for direct assessment of impact of in vivo supplementation in humans, facilitating noninvasive measurements, the administration of external challenges, and comparative ease and safety of tissue sampling. Our 3-mo supplementation trial was performed under controlled conditions, evaluating the impact of GTC ingestion on skin inflammatory status under basal conditions and after a reproducible acute UVR challenge to assess GTCs’ photoprotective potential.

In this double-blind randomized controlled trial, we found that oral GTC supplementation taken with low-dose vitamin C did not have a statistically significantly effect on the skin basal inflammatory status or the response to acute proinflammatory UVR challenge, including clinical and histologic sunburn outcomes, or their biochemical mediation through major proinflammatory eicosanoids produced via the cyclooxygenase and lipoxygenase pathways. Thus, compared with placebo, oral supplementation with GTCs for 12 wk did not reduce UVR-induced inflammation in terms of the clinical erythema response, assessed both visually as the sunburn threshold (MED) and quantitatively across the UVR erythema dose-response (AUC for UVR dose vs. erythema index). Similarly, consumption of GTCs did not have a statistically significantly effect on infiltration of neutrophils or T cells after UVR challenge. Finally, GTCs did not have a statistically significantly effect on baseline or UVR-induced concentrations of PGE2 and 12-HETE, which have roles in the mediation of sunburn vasodilation and chemotraction, respectively (9). These data were obtained from volunteers demonstrated to be compliant with their supplementation.

There are several mechanisms by which GTCs might potentially suppress the sunburn response, including down-regulation of cyclooxygenase and/or lipoxygenase expression as demonstrated in various cell models (18, 19, 37, 38). Other mechanisms include reduced production of proinflammatory and chemoattractant cytokines such as IL-1\( \alpha \) and TNF-\( \alpha \), inhibition of T-cell proliferation (36), and upregulation of antioxidants enzyme concentrations (39, 40). These activities are supported by studies in rodent models, where green tea constituents modulated nuclear transcription factor \( \kappa B \) signaling (24), attenuated UVR-induced cyclooxygenase activity (41), and reduced neutrophil migration to sites of inflammation (22, 23). Topical application of GTCs was also reported to reduce UVB-induced production of nitric oxide and hydrogen peroxide in a mouse model (42). In addition to the above, cyclooxygenase and lipoxygenase are molecular targets for other related polyphenols, with reports of reduced eicosanoid production by lipoxygenase isoforms, including 12-lipoxygenase, in vitro (43, 44).

The above mechanistic studies and our pilot human study (27) indicated examination for the impact of oral GTC supplementation on the lipoxygenase metabolite and leukocyte chemoattractant 12-HETE, alongside cutaneous leukocyte infiltration. We did not observe a statistically significant difference in neutrophil numbers between supplementation groups or any difference in 12-HETE concentrations. Although topical application of GTCs before UVR exposure was reported to reduce UVB-induced leukocyte infiltration in animal models (19, 42) and in humans (25), the current study is the first to report the impact of orally consumed GTCs on leukocyte infiltration and production of cyclooxygenase/lipoxygenase metabolites in humans, as well as after a solar-simulated radiation challenge.

The UVR erythema response findings in our double-blind randomized controlled trial are in contrast to those in our previous open, uncontrolled study indicating GTCs might protect against UVR-induced erythema. This was a modest effect, evident as a reduction of the measured erythema index at the highest dose of...
UVR tested (27), and followed supplementation with 540 mg GTC/C and 50 mg vitamin C/C (i.e., half the amount of the current study). It is important to acknowledge the limitations of open, uncontrolled studies, particularly the inability to allow for changes in outcome measures during the course of supplementation that are unrelated to consumption of the supplement. There is also the possibility of a nonlinear dose-response effect, because higher concentrations of nutritional supplementation are sometimes reported to be less effective (e.g., 200 mg vitamin E/d was more effective than 800 mg/d in enhancing T-cell responses in the elderly) (45). However, the other published human study exploring the impact of orally consumed GTCs on sunburn, which examined for and found a suppressive effect on the visual erythema threshold (i.e., after a low-dose UVR challenge) used a higher dose of GTCs (26). The participants were instructed to consume 1 L/d of a green tea beverage (1402 mg GTC with 119 mg vitamin C daily); this also contained a higher proportion of EGCG (daily: 100 mg epicatechin, 980 mg EGCG, and 238 mg epicatechin gallate) than our supplement (daily: 75 mg epicatechin, 436 mg EGCG, and 156 mg epicatechin gallate), and this may be the most biologically active GTC (46). Other differences are that in our pilot study, the subject group comprised nearly all females, raising the possibility of a sex-specific effect; the BMI of the group was lower; and the challenges posed to rigorous blinding in a beverage study.

Strengths of this study include the double-blind randomized controlled design, a statistically justified sample size, and biochemical confirmation of subject compliance. We took an oral consumption approach rather than topical application, thus eliminating the possibility of a contribution of local protection from the UVR challenge by a sunscreen effect (47) and with greater relevance to human nutrition. Objective measurement of sunburn erythema was made across the UVR dose series, enabling characterization of responses to threshold, moderate- and high-dose solar-simulated UVR, and the impact of GTCs on these. In view of ethical considerations and the range of samples taken in this study, there was not scope to take further skin tissue for assessment of target organ (i.e., skin) bioavailability of GTCs. Potentially, interindividual variability in the types of catechins and metabolites in skin post-supplementation, as demonstrated in our pilot study (27), may influence outcomes.

We conclude that in a compliant mixed-sex study population, the daily consumption of 1080 mg encapsulated GTC, equivalent to 5 cups of green tea, taken with 100 mg vitamin C, does not significantly affect the acute UVR-induced erythema (sunburn) response, dermal leukocytic infiltration, or the cutaneous production of proinflammatory cyclooxygenase and lipooxygenase metabolites. Future studies might examine EGCG dose effect, discuss the impact on other chemokines, and explore the skin content of GTCs and their metabolites.

We thank research nurse Susan Bennett, University of Manchester, for assistance with procedures involving human volunteers and Andrew Healey, University of Bradford Analytical Centre, for technical support.

The authors’ responsibilities were as follows—MDF, AN, KAC, SM, KAM, TPD, and REBW: conducted the research and analyzed data; GW and LER: designed the research; MDF: performed randomization and statistical analyses; MDF and LER: wrote the manuscript; AN and GW: contributed to revisions of the manuscript; LER: had primary responsibility for final content; and all authors: read and approved the final manuscript. The authors declared no conflicts of interest.

REFERENCES


